.svg)
Female Hypogonadism and the Hormones That Map the Ovarian Axis
Female hypogonadism means the ovaries aren’t producing enough sex hormones or ovulating reliably. Blood biomarkers let us read the brain–pituitary–ovary communication system (hypothalamic–pituitary–ovarian, HPO axis) and locate where the signal is faltering. Estradiol (E2) is the ovary’s main estrogen and reflects follicle activity and endometrial readiness. Progesterone marks whether ovulation and corpus luteum function have occurred. The pituitary messengers—follicle-stimulating hormone and luteinizing hormone (FSH, LH)—show how strongly the brain is driving the ovary. Anti-Müllerian hormone (AMH), made by small follicles, gives a steady view of the remaining egg pool (ovarian reserve). Androgen measures—testosterone and dehydroepiandrosterone sulfate (DHEA-S)—highlight ovarian or adrenal influences that can disrupt normal cycles, while sex hormone–binding globulin (SHBG) sets how much hormone is freely active. Prolactin and thyroid signals can mute the HPO axis and are checked because they change reproductive hormones upstream. Together, these biomarkers create a coherent story of hormone supply, demand, and delivery, helping distinguish ovarian causes from central (hypothalamic or pituitary) causes of low estrogen function.
Reading an HPO Axis Panel
Female hypogonadism blood tests map the brain–ovary conversation that powers cycles, fertility, bone strength, mood, metabolism, and cardiovascular health. Measuring LH, FSH, estradiol, and progesterone shows whether the pituitary can signal, the ovaries can respond, and whether ovulation actually occurs—insight that reaches far beyond periods.In a typical reproductive cycle, follicular-phase LH is about 2–12 and FSH 3–10, with estradiol around 30–120, rising to 150–500 just before ovulation alongside a brief LH surge. Luteal-phase estradiol sits near 60–250, while progesterone climbs to about 5–20, reflecting ovulation; follicular progesterone is low. Optimal values generally sit in the middle of each phase’s range, with luteal progesterone toward the higher end after ovulation. After menopause, estradiol and progesterone are low while FSH and LH are high. In pregnancy, estradiol and progesterone are markedly higher than nonpregnant ranges.When these values are low, the physiology points to under-signaling or under-response. Low LH/FSH with low estradiol/progesterone indicates hypothalamic–pituitary suppression (stress, undernutrition, high training load, pituitary disease), leading to irregular or absent periods, low libido, hot flashes, sleep and mood changes, and bone loss; in teens, this can delay or halt puberty and stunt peak bone mass. Low estradiol with high FSH/LH suggests primary ovarian insufficiency, mimicking early menopause with infertility and vasomotor symptoms. Low luteal progesterone signals anovulation or a weak corpus luteum, with short cycles, spotting, and difficulty conceiving. Persistently high LH relative to FSH outside the midcycle surge can be seen in polycystic ovary syndrome; unusually high estradiol may reflect functional cysts. Big picture, these hormones integrate the neuroendocrine, reproductive, skeletal, and cardiometabolic systems. Tracking them clarifies risks for infertility, osteoporosis, adverse pregnancy outcomes, and long-term cardiometabolic disease, and it guides when to look at related axes like thyroid, prolactin, insulin, and adrenal function.
What an HPO Workup Can and Can't Tell You
Female hypogonadism blood testing provides a window into the hormonal systems that drive energy, metabolism, cardiovascular health, cognition, reproduction, and immune function. At Superpower, we measure four key biomarkers—luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, and progesterone—to assess the integrity of the hypothalamic-pituitary-ovarian (HPO) axis. This axis orchestrates the production and regulation of sex hormones, which are essential for menstrual cycles, fertility, bone strength, and overall systemic balance.LH and FSH are signaling hormones produced by the pituitary gland. They stimulate the ovaries to produce estradiol and progesterone, the primary female sex hormones. In female hypogonadism, this communication can be disrupted, leading to low levels of estradiol and progesterone, or abnormal patterns of LH and FSH. These changes can signal whether the issue originates in the ovaries (primary hypogonadism) or higher up in the brain (secondary hypogonadism).Balanced levels of LH, FSH, estradiol, and progesterone are crucial for stable menstrual cycles, ovulation, and the maintenance of bone and cardiovascular health. Disruptions in these hormones can affect mood, cognition, metabolism, and immune resilience, reflecting the broad impact of the HPO axis on overall health.Interpretation of these biomarkers depends on factors such as age, menstrual cycle phase, pregnancy, menopause, acute illness, and certain medications. Laboratory methods and reference ranges may also vary, so results are best understood in context.
FAQs
It checks how well your ovaries make hormones and how well your brain signals them. We measure the pituitary signals (LH, FSH) and ovarian hormones (estradiol, progesterone) to assess the hypothalamic–pituitary–ovarian axis. Superpower tests your blood for LH, FSH, Estradiol, and Progesterone.
It explains irregular or absent periods, hot flashes, low libido, infertility, or bone concerns by showing if low estrogen comes from the ovaries or the brain. Patterns in LH, FSH, estradiol, and progesterone distinguish primary ovarian causes from hypothalamic–pituitary causes and confirm ovulation status.
Yes. With Superpower, our team member can organize a professional blood draw in your home and manage the entire process.
Start with a baseline panel timed to your cycle, then repeat if results are borderline, inconsistent with symptoms, or after any major change (medications, cycle pattern). If you are tracking ovulation, check mid‑luteal progesterone in a separate cycle for confirmation. Ongoing testing is guided by clinical context or treatment monitoring.
Cycle phase, pregnancy, perimenopause/menopause, and hormonal contraception or HRT change LH, FSH, estradiol, and progesterone. Hypothalamic–pituitary disorders, primary ovarian insufficiency, PCOS, thyroid disease, and high prolactin states shift results. Medications (glucocorticoids, opioids, antipsychotics), acute illness, weight change, intense exercise, and high‑dose biotin can also affect assays. Timing and lab methods matter.
No fasting is needed. For baseline ovarian function, test LH/FSH/E2 on cycle days 2–5; for ovulation, test progesterone about 7 days before your next period. Note your cycle day and any hormones you take, and avoid high‑dose biotin for 48 hours. Morning draws improve consistency.
References
- Panay, N., Anderson, R. A., Bennie, A., Cedars, M., Davies, M., Ee, C., Gravholt, C. H., Kalantaridou, S., Kallen, A., Kim, K. Q., Misrahi, M., Mousa, A., Nappi, R. E., Rocca, W. A., Ruan, X., Schubert, M., Sopa, N., Vermeulen, R., & Vogt, E. C. (2024). Evidence-based guideline: Premature ovarian insufficiency. Human Reproduction Open, 2024(4), hoae065. https://doi.org/10.1093/hropen/hoae065
- Practice Committee of the American Society for Reproductive Medicine. (2020). Testing and interpreting measures of ovarian reserve: A committee opinion. Fertility and Sterility, 114(6), 1151-1157. https://doi.org/10.1016/j.fertnstert.2020.09.134
- Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism, 108(10), 2447-2469. https://doi.org/10.1210/clinem/dgad463
- Gordon, C. M., Ackerman, K. E., Berga, S. L., Kaplan, J. R., Mastorakos, G., Misra, M., Murad, M. H., Santoro, N. F., & Warren, M. P. (2017). Functional hypothalamic amenorrhea: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 102(5), 1413-1439. https://doi.org/10.1210/jc.2017-00131
- National Institute of Child Health and Human Development. (n.d.). Primary ovarian insufficiency (POI). https://www.nichd.nih.gov/health/topics/poi
.avif)
.svg)
.svg)
